검색
Alkermes Plc
ALKS관심 목록에 추가
38.800USD
+0.510+1.33%
시장 운영 시간 （ET）시세는 15분 지연됩니다
6.43B시가총액
41.73P/E TTM
자세한 내용은 Alkermes Plc 회사
Alkermes plc is Ireland-based biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.
Alkermes Plc 정보
종목 코드 ALKS
회사 이름Alkermes Plc
상장일Jul 16, 1991
CEOPops (Richard F)
직원 수1800
유형Ordinary Share
회계 연도 종료Jul 16
주소Connaught House
도시DUBLIN
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가Ireland
우편 번호D04 C5Y6
전화35317728000
웹사이트https://www.alkermes.com/
종목 코드 ALKS
상장일Jul 16, 1991
CEOPops (Richard F)
Alkermes Plc의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Mr. Richard F. Pops
Mr. Richard F. Pops
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
1.38M
--
Mr. David Joseph Gaffin
Mr. David Joseph Gaffin
Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary
Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary
231.56K
-0.88%
Mr. Shane M. Cooke
Mr. Shane M. Cooke
Independent Director
Independent Director
103.74K
--
Dr. Craig C. Hopkinson, M.D.
Dr. Craig C. Hopkinson, M.D.
Executive Vice President, Research and Development and Chief Medical Officer
Executive Vice President, Research and Development and Chief Medical Officer
81.39K
-4.91%
Mr. Frank Anders (Andy) Wilson, CPA
Mr. Frank Anders (Andy) Wilson, CPA
Lead Independent Director
Lead Independent Director
31.08K
--
Dr. Cato T. Laurencin, M.D., Ph.D.
Dr. Cato T. Laurencin, M.D., Ph.D.
Independent Director
Independent Director
29.10K
--
Dr. Christopher I. Wright, M.D., Ph.D.
Dr. Christopher I. Wright, M.D., Ph.D.
Independent Director
Independent Director
23.01K
--
Ms. Nancy S. Lurker
Ms. Nancy S. Lurker
Independent Director
Independent Director
13.55K
+21.03%
Dr. Nancy L. Snyderman, M.D.
Dr. Nancy L. Snyderman, M.D.
Independent Director
Independent Director
--
--
Mr. C. Todd Nichols
Mr. C. Todd Nichols
Senior Vice President, Chief Commercial Officer
Senior Vice President, Chief Commercial Officer
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Mr. Richard F. Pops
Mr. Richard F. Pops
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
1.38M
--
Mr. David Joseph Gaffin
Mr. David Joseph Gaffin
Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary
Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary
231.56K
-0.88%
Mr. Shane M. Cooke
Mr. Shane M. Cooke
Independent Director
Independent Director
103.74K
--
Dr. Craig C. Hopkinson, M.D.
Dr. Craig C. Hopkinson, M.D.
Executive Vice President, Research and Development and Chief Medical Officer
Executive Vice President, Research and Development and Chief Medical Officer
81.39K
-4.91%
Mr. Frank Anders (Andy) Wilson, CPA
Mr. Frank Anders (Andy) Wilson, CPA
Lead Independent Director
Lead Independent Director
31.08K
--
Dr. Cato T. Laurencin, M.D., Ph.D.
Dr. Cato T. Laurencin, M.D., Ph.D.
Independent Director
Independent Director
29.10K
--
수익 분석
통화: USD마지막 업데이트: Mon, Apr 6
통화: USD마지막 업데이트: Mon, Apr 6
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
사업별USD
이름
수익
비율
VIVITROL
467.91M
31.70%
ARISTADA
370.04M
25.07%
LYBALVI
346.69M
23.49%
Royalty Revenue - VUMERITY
113.93M
7.72%
Royalty-INVEGA SUSTENNA/XEPLION & INVEGA TRINZA/TREVICTA
109.57M
7.42%
기타
67.75M
4.59%
지역별USD
이름
수익
비율
United States
1.37B
93.01%
Rest of the World
102.36M
6.94%
Ireland
754.00K
0.05%
사업별
지역별
사업별USD
이름
수익
비율
VIVITROL
467.91M
31.70%
ARISTADA
370.04M
25.07%
LYBALVI
346.69M
23.49%
Royalty Revenue - VUMERITY
113.93M
7.72%
Royalty-INVEGA SUSTENNA/XEPLION & INVEGA TRINZA/TREVICTA
109.57M
7.42%
기타
67.75M
4.59%
주식 보유 통계
마지막 업데이트: Thu, May 7
마지막 업데이트: Thu, May 7
주주
주주 유형
주주
주주
비율
BlackRock Institutional Trust Company, N.A.
14.44%
Baker Bros. Advisors LP
6.01%
Vanguard Portfolio Management, LLC
5.71%
State Street Investment Management (US)
5.68%
T. Rowe Price Associates, Inc.
5.28%
기타
62.88%
주주
주주
비율
BlackRock Institutional Trust Company, N.A.
14.44%
Baker Bros. Advisors LP
6.01%
Vanguard Portfolio Management, LLC
5.71%
State Street Investment Management (US)
5.68%
T. Rowe Price Associates, Inc.
5.28%
기타
62.88%
주주 유형
주주
비율
Investment Advisor
53.52%
Investment Advisor/Hedge Fund
29.75%
Hedge Fund
19.22%
Research Firm
2.49%
Pension Fund
2.14%
Individual Investor
1.41%
Sovereign Wealth Fund
1.17%
Bank and Trust
0.48%
Private Equity
0.42%
기관 주식 보유
마지막 업데이트: Wed, Apr 1
마지막 업데이트: Wed, Apr 1
보고 기간
기관 수
보유 주식
비율
변동
2026Q1
783
182.39M
109.43%
-12.00M
2025Q4
744
175.23M
117.54%
-23.12K
2025Q3
767
175.30M
122.16%
+2.11M
2025Q2
769
173.38M
125.62%
-4.15M
2025Q1
759
177.46M
124.05%
-27.05M
2024Q4
734
172.08M
130.58%
-12.03M
2024Q3
705
184.36M
134.23%
-884.11K
2024Q2
687
185.17M
126.42%
+3.87M
2024Q1
659
181.61M
124.10%
-28.36M
2023Q4
633
182.01M
111.83%
+12.84M
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
BlackRock Institutional Trust Company, N.A.
24.07M
14.44%
+417.41K
+1.76%
Dec 31, 2025
Baker Bros. Advisors LP
10.01M
6.01%
+1.92M
+23.74%
Dec 31, 2025
State Street Investment Management (US)
9.47M
5.68%
+932.51K
+10.92%
Dec 31, 2025
T. Rowe Price Associates, Inc.
8.80M
5.28%
-1.25M
-12.41%
Dec 31, 2025
Renaissance Technologies LLC
6.67M
4%
+375.50K
+5.97%
Dec 31, 2025
American Century Investment Management, Inc.
5.96M
3.57%
+1.56M
+35.46%
Dec 31, 2025
JP Morgan Asset Management
4.83M
2.9%
+1.21M
+33.37%
Dec 31, 2025
Dimensional Fund Advisors, L.P.
4.41M
2.65%
+714.79K
+19.33%
Dec 31, 2025
더 보기
관련 ETF
마지막 업데이트: Sat, Dec 6
마지막 업데이트: Sat, Dec 6
이름
비율
AdvisorShares Psychedelics ETF
7.31%
iShares Neuroscience and Healthcare ETF
3.82%
First Trust NYSE Arca Biotechnology Index Fund
3.3%
Invesco S&P SmallCap Health Care ETF
3.1%
ALPS Medical Breakthroughs ETF
2.07%
Knowledge Leaders Developed World ETF
1.69%
Langar Global HealthTech ETF
1.44%
State Street SPDR S&P Biotech ETF
1.35%
Abacus FCF International Leaders ETF
1.34%
Invesco S&P SmallCap Quality ETF
1.32%
더 보기
AdvisorShares Psychedelics ETF
비율7.31%
iShares Neuroscience and Healthcare ETF
비율3.82%
First Trust NYSE Arca Biotechnology Index Fund
비율3.3%
Invesco S&P SmallCap Health Care ETF
비율3.1%
ALPS Medical Breakthroughs ETF
비율2.07%
Knowledge Leaders Developed World ETF
비율1.69%
Langar Global HealthTech ETF
비율1.44%
State Street SPDR S&P Biotech ETF
비율1.35%
Abacus FCF International Leaders ETF
비율1.34%
Invesco S&P SmallCap Quality ETF
비율1.32%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
배당락일
유형
비율
데이터 없음
날짜
배당락일
유형
비율
데이터 없음
